Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,656 matching trials from the live ClinicalTrials.gov search.
Conditions
End Stage Renal Disease, Arteriovenous Fistula, Arteriovenous Graft
Interventions
Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Results available

Acid-Base Composition With Use of hemoDialysates

NCT02334267
Conditions
End Stage Renal Disease
Interventions
Group 1: GranuFlo, Group 2: NaturaLyte
Device
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Kidney Disease, Chronic
Interventions
culturally informed care coordination intervention, No Intervention - Usual Care Group
Behavioral · Other
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more
Completed Phase 2Phase 3 Interventional Results available

Alkali Therapy in Chronic Kidney Disease

NCT01452412
Conditions
Chronic Kidney Disease, Metabolic Acidosis
Interventions
Sodium bicarbonate, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
19 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
The Bronx, New York • Cleveland, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Impairment in Kidney Disease

NCT00905619
Conditions
Kidney Insufficiency, Chronic
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Conditions
Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Conditions
End-stage Kidney Disease
Interventions
Talking About Living Kidney Donation, Kidney Transplant Fast Track
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Conditions
Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
Interventions
Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Sirolimus
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
End Stage Renal Disease
Interventions
oxygen
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Timing of return of results
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
6,789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 7 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Meridian, Idaho
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Conditions
Anemia of Chronic Kidney Disease
Interventions
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
Conditions
Acute Renal Failure, Chronic Renal Failure
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

NCT04994522
Conditions
End Stage Renal Disease, Renal Impairment
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Chronic Kidney Disease
Interventions
Mindfulness
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut